USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: VICAL, INC.
City: SAN DIEGO
State: CA
Zip+4: 92121
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,235,492.00 5
SBIR Phase II $3,637,138.00 2
STTR Phase I $862,534.00 3
STTR Phase II $7,674,480.00 2

Award List:

OPTIMIZATION OF CATIONIC LIPID TECHNIQUES FOR THE DIRECT DELIVERY AND EXPRESSION OF GENES IN VIVO

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raj Kumar
Award Amount: $49,479.00

OPTIMIZATION OF CATIONIC LIPID TECHNIQUES FOR THE DIRECT DELIVERY AND EXPRESSION OF GENES IN VIVO

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Raj Kumar
Award Amount: $500,000.00
Abstract:
The purpose of this project is to develop an assay system with high throughput that is capable of screening the efficiency of polynucleotide delivery systems under various conditions in tissue culture. several novel cationic lipid analogs and a variety of lipid vehicle compositions will be… More

DEVELOPMENT OF NUCLEAR TARGETING DNA VACCINE VECTORS

Award Year / Program / Phase: 1999 / STTR / Phase I
Agency: HHS
Research Institution: University of South Alabama
Principal Investigator: Dean
Award Amount: $100,000.00
RI Contact: N/A

THERAPEUTIC DNA VACCINES TO TREAT B CELL LYMPHOMA

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter M. Hobart
Award Amount: $271,457.00
Abstract:
Not Available The proposed Phase I program will design active noise and vibration reduction systems for the Advanced Amphibious Assault Vehicle (AAAV) in order to satisfy specific performance-based objectives. Those objectives are: 1) maintain safe exposure limits for all AAAV personnel (crew and… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter M. Hobart
Award Amount: $150,769.00

PROPHYLACTIC ANTHRAX TOXIN VACCINE

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: OHIO STATE UNIVERSITY
Principal Investigator: Peter M. Hobart
Award Amount: $462,918.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This STTR grant proposal is for the development of a safe and efficacious Anthrax Toxin Vaccine. The present world-wide threat of the use of anthrax spores as a bioterrorist weapon in military theaters as well as on the general population has focused attention on… More

Prophylactic Anthrax Toxin Vaccine

Award Year / Program / Phase: 2003 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator: Peter M. Hobart
Award Amount: $5,674,947.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Vical Inc. seeks SBIR Phase II funding to develop and produce a licensable prophylactic anthrax vaccine. This project will move on an accelerated but realistic timeline with plans for human clinical trials to begin in September 2003. Although many candidate… More

Development of a Cytomegalovirus DNA Vaccine

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas G. Evans
Award Amount: $263,787.00
Abstract:
DESCRIPTION (provided by applicant): The specific AIM of this Phase I SBIR proposal from Vical Incorporated is to move forward an immunotherapeutic vaccine for cytomegalovirus (CMV) from preclinical to clinical development. Vical has undertaken a program that focuses on the prevention of CMV… More

CMV Immunotherapeutic Vaccine

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: David C. Kaslow
Award Amount: $3,137,138.00
Abstract:
DESCRIPTION (provided by applicant): Vical Inc. of San Diego, Ca. is the largest GMP manufacturer of plasmid DNA for vaccine clinical trials in the world. We have manufactured GMP plasmid DNA vaccines that are being used or entering clinical trials for HIV (in the US and China), malaria (up to 9… More

Development of a DNA Vaccine Against Influenza Virus

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lawrence R. Smith
Award Amount: $500,000.00
Abstract:
DESCRIPTION (provided by applicant): The likely emergence of natural influenza pandemic viruses and the recent expansion of influenza-infected animal carrier reservoirs argue for the rapid development and stockpile of an effective universal influenza vaccine. Currently, no vaccine or other treatment… More

Herpes Simplex Immunotherapeutic Vaccine

Award Year / Program / Phase: 2008 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $1,999,533.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Herpes simplex viruses infect humans worldwide. In the US, herpes simplex virus type 2 (HSV-2) infects about 17% of adults. Rates are far higher in the developing world, especially in populations with high HIV-1 prev alence. HSV-2 infections are permanent and… More